Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
A judge at the US District Court for the Northern District of California has denied Amgen’s attempt to block entry of a biosimilar version of its drug Neupogen.   23 March 2015
Big Pharma
Orphan medicinal products in Europe benefit from a range of incentives, but the greatest of these is the promise of receiving a ten-year period of true market exclusivity, says Trevor Cook of Wilmer Cutler Pickering Hale and Dorr.   20 March 2015
Americas
Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.   20 March 2015
Big Pharma
Intellectual property is still seen as a “dirty term” in the EU, the assistant general counsel of pharmaceutical company GlaxoSmithKline has claimed.   19 March 2015
Americas
A US district court yesterday gave its opinion on how a group of disputed patent claims must be construed in a patent infringement case between Eisai and Novartis and several generic drug makers.   18 March 2015
Americas
Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.   17 March 2015
Europe
Law firm Cooley has added to its newly-opened London office with the hire of life sciences lawyers John Wilkinson and Nicola Maguire.   17 March 2015
Americas
The US Court of Appeals for the Federal Circuit yesterday threw out a damages sum of $48 million, some of which had been awarded to Yale University, finding that a lower court did not properly interpret the claims in the disputed patent.   17 March 2015
Americas
Florida-based healthcare company Diabetic Care RX, which operates as Patient Care America, has asked for a declaratory judgment that it does not infringe a patent owned by Pentec Health by providing nutritional supplements to dialysis clinics.   16 March 2015
Big Pharma
An Advocate General in the Court of Justice of the European Union, Niilo Jääskinen, has clarified how the regulation for supplementary protection certificates should be interpreted concerning medicinal products made with a combination of active ingredients.   13 March 2015